Pfizer Oncology Head Charles Baum: An Interview With “The Pink Sheet”
Executive Summary
In an interview with "The Pink Sheet," Charles Baum highlights several of Pfizer's late-stage oncology drugs in development, including axitinib in pancreatic cancer and tremelimumab for metastatic melanoma, and discusses the way Pfizer's R&D strategy for oncology is evolving. Baum is VP and head of the Oncology Therapeutic Area at Pfizer Global Research. Prior to joining Pfizer in 2003 he was senior director of oncology at Schering-Plough.
You may also be interested in...
AstraZeneca CTLA-4 Inhibitor Imjudo (Finally) Wins FDA Approval
More than a decade after Pfizer gave up on it, tremelimumab won approval combined with PD-L1 inhibitor Imfinzi for frontline hepatocellular carcinoma, ahead of Bristol’s Yervoy/Opdivo second-line indication.
Pfizer Restructures for a More Flexible Future
In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care, and emerging markets. These units join Pfizer's oncology and mature products businesses.
Bristol’s Take On Restructuring: Cut $1.5 Bil. In Costs, Try BioPharma Model
Following a strategic review of Bristol-Myers Squibb's business, the company's management unveiled a productivity initiative Dec. 5 designed to cut $1.5 billion in costs and fashion the drug maker into a "next-generation biopharma.